Table 3

Incidence rate ratios (IRRs) from trials of sirolimus and paclitaxel eluting stents and ratio of incidence rate ratios (RIRR) comparing sirolimus with paclitaxel in all patients

Study	IRR (95% confidence interval)
Study	In-stent restenosis	In-segment restenosis	TLR	MACE
*I², test of heterogeneity.
MACE, major adverse cardiac events; TLR, target lesion revascularisation.
Sirolimus trials
SIRIUS (2003)⁴	0.09 (0.05 to 0.16)	0.24 (0.16 to 0.36)	0.24 (0.15 to 0.39)	0.38 (0.26 to 0.55)
E-SIRIUS (2003)¹	0.09 (0.04 to 0.22)	0.14 (0.07 to 0.28)	0.19 (0.09 to 0.43)	0.35 (0.19 to 0.65)
C-SIRIUS (2004)³	0.02 (0.001 to 0.40)	0.04 (0.01 to 0.32)	0.22 (0.05 to 1.03)	0.22 (0.05 to 1.03)
DIABETES (2005)³⁰	0.15 (0.06 to 0.39)	0.22 (0.10 to 0.47)	0.24 (0.10 to 0.59)	0.31 (0.15 to 0.66)
RAVEL (2002)²	0.02 (0.001 to 0.26)	0.02 (0.001 to 0.26)	0.02 (0.001 to 0.29)	0.20 (0.09 to 0.44)
SES-SMART (2004)⁸	0.10 (0.04 to 0.23)	0.18 (0.10 to 0.34)	0.33 (0.16 to 0.70)	0.30 (0.16 to 0.57)
Combined IRR	0.10 (0.07 to 0.14)	0.20 (0.15 to 0.26)	0.24 (0.17 to 0.33)	0.33 (0.25 to 0.42)
Heterogeneity*	0.0%, p = 0.63	33.6%, p = 0.18	0.0%, p = 0.51	0.0%, p = 0.78
Paclitaxel trials
TAXUS I (2003)⁵	0.14 (0.01 to 2.67)	NA	0.14 (0.01 to 2.77)	0.25 (0.03 to 2.24)
TAXUS II (2003)^{6, 32, 33}	0.33 (0.19 to 0.55)	0.18 (0.09 to 0.36)	0.27 (0.13 to 0.53)	0.58 (0.38 to 0.86)
TAXUS IV (2004)^{7, 29}	0.23 (0.13 to 0.39)	0.30 (0.19 to 0.47)	0.32 (0.22 to 0.46)	0.56 (0.41 to 0.78)
TAXUS VI (2005)³¹	0.28 (0.17 to 0.46)	0.35 (0.22 to 0.54)	0.42 (0.25 to 0.72)	0.73 (0.48 to 1.12)
Combined IRR	0.27 (0.20 to 0.37)	0.29 (0.22 to 0.39)	0.33 (0.25 to 0.44)	0.60 (0.48 to 0.75)
Heterogeneity*	0.0%, p = 0.77	16.3%, p = 0.30	0.0%, p = 0.67	0.0%, p = 0.65
RIRR (sirolimus v paclitaxel)	0.35 (0.21 to 0.57) p<0.001	0.68 (0.45 to 1.01) p = 0.057	0.71 (0.46 to 1.09) p = 0.120	0.54 (0.39 to 0.76) p<0.001